Life sciences venture capital firm Sofinnova Partners today announced the close of its latest flagship fund, Sofinnova Capital XI, at €650 million ($750 million), greatly exceeding its initial target.
Based in Paris, London, and Milan, Sofinnova Capital XI will back a new generation of pioneering biopharmaceutical and medical technology companies addressing urgent unmet clinical needs.
Sofinnova Capital XI is actively deploying capital, with investments already made in a few portfolio companies, including Latent Labs, BioCorteX, and Amolyt.
In keeping with Sofinnova’s multi-strategy platform model, Capital XI draws on the strength of its experienced team, including Partners Maina Bhaman, Anta Gkelou, Karl Naegler, Antoine Papiernik, Henrijette Richter, and Graziano Seghezzi.
Sofinnova Capital XI attracted strong support from a global base of blue-chip institutional investors—among them sovereign wealth funds, leading pharmaceutical companies and other corporates, as well as insurance companies, foundations, and family offices.
Commitments came from across Europe, North America, Asia, and the Middle East, with a majority of returning LPs and a significant number of new top-tier investors. This reflects enduring confidence in Sofinnova’s disciplined strategy and long-standing track record.
Antoine Papiernik, Managing Partner and Chairman of Sofinnova Partners, said:
“This fundraising marks a pivotal moment for Sofinnova. It gives us the firepower to double down on early-stage opportunities and reinforces our uniquely collaborative, science-driven investment approach.
We’re excited to continue backing visionary entrepreneurs and advancing the next wave of breakthroughs in science and medicine to bring them to patients worldwide."
The fund will continue to support early-stage biotech and medtech ventures across Europe and North America, participating in both initial and follow-on rounds.
Would you like to write the first comment?
Login to post comments